{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,2]],"date-time":"2025-03-02T05:10:10Z","timestamp":1740892210276,"version":"3.38.0"},"reference-count":5,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T00:00:00Z","timestamp":1713225600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007273","name":"Medical College, Weill Cornell Medicine","doi-asserted-by":"publisher","award":["UL1TR002384"],"award-info":[{"award-number":["UL1TR002384"]}],"id":[{"id":"10.13039\/100007273","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jaadinternational.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JAAD International"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.jdin.2024.04.004","type":"journal-article","created":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T15:53:04Z","timestamp":1715356384000},"page":"183-185","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Low rate of seroconversion analyzing QuantiFERON TB-gold testing in patients with psoriasis and hidradenitis suppurativa taking biologic therapy at an academic center in New York City"],"prefix":"10.1016","volume":"16","author":[{"given":"Apostolos","family":"Katsiaunis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jade","family":"Conway","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Debra","family":"D'Angelo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5913-9304","authenticated-orcid":false,"given":"Shari R.","family":"Lipner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2022","series-title":"State & Local Data","key":"10.1016\/j.jdin.2024.04.004_bib1"},{"issue":"3","key":"10.1016\/j.jdin.2024.04.004_bib2","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1111\/bjd.18461","article-title":"Utility of repeat latent tuberculosis testing with the QuantiFERON-TB Gold test in patients with psoriasis treated with tumour necrosis factor-\u03b1 inhibitors at a single U.S. institution","volume":"182","author":"Ya","year":"2020","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.jdin.2024.04.004_bib3","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jaad.2018.03.025","article-title":"Low conversion rate of QuantiFERON-TB Gold screening tests in patients treated with tumor necrosis factor inhibitors: a retrospective cohort study identifying an important practice gap","volume":"79","author":"Chung","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"10.1016\/j.jdin.2024.04.004_bib4","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0184178","article-title":"Serial QuantiFERON-TB Gold testing in patients with psoriasis treated with ustekinumab","volume":"12","author":"Hsiao","year":"2017","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.jdin.2024.04.004_bib5","doi-asserted-by":"crossref","DOI":"10.1111\/dth.14699","article-title":"Serial Quantiferon-TB Gold test results in 279 patients with psoriasis receiving biologic therapy","volume":"34","author":"Akdogan","year":"2021","journal-title":"Dermatol Ther"}],"container-title":["JAAD International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666328724000713?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666328724000713?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,2]],"date-time":"2025-03-02T03:59:36Z","timestamp":1740887976000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666328724000713"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":5,"alternative-id":["S2666328724000713"],"URL":"https:\/\/doi.org\/10.1016\/j.jdin.2024.04.004","relation":{},"ISSN":["2666-3287"],"issn-type":[{"type":"print","value":"2666-3287"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Low rate of seroconversion analyzing QuantiFERON TB-gold testing in patients with psoriasis and hidradenitis suppurativa taking biologic therapy at an academic center in New York City","name":"articletitle","label":"Article Title"},{"value":"JAAD International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdin.2024.04.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by the American Academy of Dermatology, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}